Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have a major impact on cancer treatment. However, the therapeutic efficacy of ICIs is only effective in some patients. Programmed death ligand 1 (PD-L1), tumor mutation burden (TMB), and high-frequency microsatellite instability (MSI-high) are markers that predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Kazuyuki, Tsunoda, Takuya, Yoshimura, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410458/
https://www.ncbi.nlm.nih.gov/pubmed/36013407
http://dx.doi.org/10.3390/life12081229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410458/
https://www.ncbi.nlm.nih.gov/pubmed/36013407
http://dx.doi.org/10.3390/life12081229

Ejemplares similares